In race for in vivo sickle cell cure, Intellia unveils (very) early proof-of-concept

In race for in vivo sickle cell cure, Intellia unveils (very) early proof-of-concept

Source: 
Endpoints
snippet: 

Intellia, one of the first big CRISPR companies, unveiled one new approach to reaching that simple IV at a scientific conference Wednesday. The biotech used custom lipid nanoparticles — those now–famous tiny bubbles of fat — to carry CRISPR into the bone marrow of mice and edit stem cells there. After repeated dosing, the company’s scientists said they were able to edit more than enough cells to provide a functional cure for sickle cell.